文献速递咽喉与嗓音

声带注射内移术使用丝素微颗粒-透明质酸材料后超过12个月的前瞻性结局

Prospective >12 Months Outcomes After Vocal Fold Injection Medialization With Silk Microparticle-Hyaluronic Acid Material.
PubMed 文献 · Laryngoscope · 2023-09-07

这项前瞻性开放标签研究纳入17例单侧声带麻痹患者,接受丝素微颗粒-透明质酸材料声带注射内移术,其中12例随访≥12个月。7例在注射后≥12个月显示持续治疗获益,嗓音障碍指数VHI-10中位改善19分(p=0.0156), blinded评估显示5/7例声门闭合完全或接近完全;另7例在注射后3-4个月出现初期获益后效果减退。

要点

  • 丝素微颗粒-透明质酸材料声带注射内移术可在部分单侧声带麻痹患者中维持超过12个月的嗓音相关获益。
  • 7例患者注射后≥12个月VHI-10中位改善19分(p=0.0156),1个月至12个月间VHI-10无显著变化。
  • 7例患者在注射后3-4个月出现初期获益后效果减退,预测持续应答的临床因素尚需进一步探索。

核心结论

  • 丝素微颗粒-透明质酸材料声带注射内移术可为单侧声带麻痹患者提供超过12个月的嗓音相关结局持续改善。
  • 部分接受丝素微颗粒-透明质酸材料治疗的患者在注射后约3-4个月出现效果早期减退。
  • 预测丝素微颗粒-透明质酸材料注射持续治疗应答的临床因素尚需进一步探索。

研究设计与样本

  • 前瞻性开放标签研究,纳入选择接受丝素微颗粒-透明质酸材料声带注射内移术的单侧声带麻痹患者。
  • 共17例单侧声带麻痹患者接受丝素微颗粒-透明质酸材料声带注射内移术,其中12例随访≥12个月。
  • 由盲法专家对喉频闪镜检查进行评级。
  • 证据等级:3级。

主要发现

  • 17例患者中12例有≥12个月随访,其中7例在注射后≥12个月显示持续治疗获益,VHI-10中位改善19分(p=0.0156)。
  • 这7例患者中,VHI-10在1个月与12个月之间无显著变化。
  • 盲法评级显示,7例VHI-10持续改善的患者中5例在12个月时声门闭合完全或接近完全。
  • 7例患者中2例在12个月时存在小(<1 mm)声门裂隙。
  • 7例患者在注射后3-4个月出现初期获益后效果减退。

局限性

  • 预测丝素微颗粒-透明质酸材料注射持续治疗应答的临床因素尚需进一步探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Vocal fold injection medialization (VFIM) is widely used as an initial treatment for unilateral vocal fold paralysis (UVFP). Current practices employ materials that share the limitation of temporary clinical effect from variable resorption rates. A novel silk protein microparticle-hyaluronic acid-based material (silk-HA) has demonstrated cellular infiltration and tissue deposition that may portend a durable medialization effect. We report on ≥12 months outcomes after VFIM with silk-HA. METHODS: Prospective open-label study of patients with UVFP that elected treatment with VFIM with silk-HA. Blinded experts rated laryngeal stroboscopic exams. RESULTS: Seventeen patients with UVFP underwent VFIM with silk-HA. Twelve of the 17 patients have ≥12 months follow-up. Seven patients demonstrated durable treatment benefit ≥12 months after injection with median improvement of 19 (p = 0.0156) in VHI-10. There was no significant change in VHI-10 between 1 and 12 months for these patients. Blinded ratings indicated that 5/7 patients with sustained improvements in VHI-10 exhibited complete or touch glottal closure at 12 months. Two of the seven patients exhibited a small (<1 mm) glottal gap at 12 months. Seven patients experienced initial benefit with later regression 3-4 months after injection. CONCLUSION: VFIM with silk-HA can offer durable improvement in voice-related outcomes for UVFP past 12 months. A subset of patients treated with silk-HA experienced early loss of effect around 3-4 months postinjection. Clinical factors predictive of sustained treatment response to silk-HA injection require further exploration. LEVEL OF EVIDENCE: 3 Laryngoscope, 134:3679-3685, 2024.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Gao WZ, Paoletti MF, Bensoussan Y, et al. Prospective >12 Months Outcomes After Vocal Fold Injection Medialization With Silk Microparticle-Hyaluronic Acid Material. Laryngoscope. 2023. PMID: 37676072. doi:10.1002/lary.31039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。